Viking's key drug demonstrated excellent body weight reduction data in a phase 2 trial, but its safety and tolerability data ...

Viking Therapeutics (VKTX) stock drops as its oral obesity drug VK2735 trails Novo's (NVO) oral Wegovy and Lilly's (LLY) ...

Viking Therapeutics said Tuesday its experimental weight-loss pill helped patients lose 12.2% of their body weight in a ...

We recently published 10 Stocks Hammered Harder Than Wall Street. Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of Tuesday’s ...

Viking Therapeutics' stock drops 40% despite strong Phase 2 weight-loss drug results. See here to know why I remain ultra bullish on VKTX stock.

Viking Therapeutics’ VK2735 achieves a 10.9% placebo-adjusted weight loss at 13 weeks, but a less than ideal safety profile ...

The company’s market value was nearly cut in half following trial results showing higher rates of treatment discontinuations ...

The Phase II VENTURE-Oral Dosing study of VK2735 met primary and secondary endpoints, with once-daily treatment leading to progressive weight reductions, high responder rates, and encouraging safety ...

Viking shares fell on Phase 2 obesity pill data as tolerability issues surfaced, but William Blair says the stock's sell-off ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...